StockData
PRENasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as PRENW

Prenetics Global Ltd

Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$19.02+0.50 (+2.70%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About Prenetics Global

Pharmaceutical Preparations, SIC 2834

Prenetics is a consumer health and longevity enterprise that develops science-backed nutritional products and genetic testing solutions. The organization operates through two primary business units: IM8, its core consumer health brand, and CircleDNA, its prevention brand. IM8 provides daily nutritional and cellular health supplements, including all-in-one daily formulations, longevity supplements, and bundled regimens. CircleDNA delivers personalized genetic testing kits using next-generation sequencing across health, wellness, and disease risk categories. The company sells its offerings directly to retail consumers worldwide through proprietary e-commerce platforms and subscription plans.

Incorporated in the Cayman Islands, Prenetics maintains its corporate registered office in Quarry Bay, Hong Kong. The business serves a global customer base across more than 30 countries, with primary international distribution markets that include the United States, Canada, the United Kingdom, Australia, and Singapore. Its dietary supplements are manufactured in third-party facilities located in the United States and shipped to consumers globally.

Summary of the business section of Prenetics Global's latest annual report, written by StockData.

Company profile

Company

Legal name
Prenetics Global Ltd
Founded
2014
Headquarters
Quarry Bay, K3
Address
7/F, K11 Atelier, 728 King'S Road 000000
Phone
(852) 2210-7188
Employees
98, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Deloitte Touche Tohmatsu, Hong Kong

Stock & identifiers

Ticker
PRE
Other tickers
PRENW
Exchange
Nasdaq
Shares outstanding
17M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-15 reverse, May 1, 2024; 1-for-15 reverse, Nov 14, 2023
SEC CIK
1876431
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Danny Sheng Wu YeungChief Executive Officer, Director1,682,207
Thuan Yen TatVP, Finance of IM8 (US) LLC–
Brian J. RosinCFO of IM8 (US) LLC23,100
Hoi Chun LoChief Financial Officer566,013
Hudson Blake LeograndeDirector6,001
Caroline S. LevyDirector–
Yin Pan ChengDirector59,051
David VanderveenDirector46,897
Darshan Ravindra ShahDirector4,506

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 98 full-time employees and 30 service contractors across eight countries, including Hong Kong, Malaysia and the United States.”

Corporate history

Events identified from SEC filings